Hemodialysis
This article was originally published in The Gray Sheet
Executive Summary
Acute onset of severe neurological symptoms is linked to hemodialysis treatment with aged dialyzers, according to investigators from FDA and the Centers for Disease Control and Prevention. A study published in the April 26 Journal of the American Medical Association shows that seven patients at one hospital developed decreased vision, hearing, conjunctivitis and headache 7-24 hours after hemodialysis on machines that contained aged cellulose acetate membranes of dialyzers, which allowed cellulose acetate degradation products to enter the blood. Dialysis centers have been advised to rotate their stocks of dialyzers, and manufacturers are being asked by FDA to place a date of manufacture on each device. The agency is working with industry to develop standards on the shelf-life of dialyzers to address the problem
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.